All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

FDA recommended to continue work on postmarket safety issues

December 18, 2009
By Angie Drakulich
Article

Pharmaceutical Technology Europe

The Government Accountability Organization (GAO) has recommended the FDA Commissioner to develop a comprehensive plan for transferring additional regulatory authorities from the Office of New Drugs (OND) to the Office of Surveillance and Epidemiology (OSE) to help address weaknesses in the agency?s oversight of postmarket drug safety.

The Government Accountability Organization (GAO) has recommended that the FDA Commissioner develop a comprehensive plan for transferring additional regulatory authorities from the Office of New Drugs (OND) to the Office of Surveillance and Epidemiology (OSE) to help address weaknesses in the agency’s oversight of postmarket drug safety. The plan should include timefames and steps to ensure resources are properly aligned, says a report from the GAO.

The GAO has made several recommendations regarding the FDA’s postmarketing work over the past few years, including a 2006 report that the agency better define the roles of the OND and OSE offices. In this new report, GAO examines what the FDA is doing to improve its decision-making regarding the safety of marketed drugs, its access to data on drug safety issues and its capacity to fulfil its postmarket drug safety workload.

Overall, the GAO notes that although the FDA is "beginning to address previously identified weaknesses in its oversight of postmarket drug safety issues…challenges remain." Some positive steps include the agency’s Safety First Initiative, which involves formalizing interactions between the OND and OSE, and providing the OSE with added responsibilities. To date, the FDA has transferred premarket review responsibility from the OND to OSE, and plans to transfer to additional postmarket responsibilities (for reviewing certain types of drug safety studies).

"The FDA is also revising its programme for resolving scientific disputes, but these changes have not increased its independence, as GAO recommended," explained a previous report.The FDA also plans to implement new systems in 2010 to improve the timeliness, quality and analysis of reports of adverse events associated with human drug use; to increase funding for contracts with private companies; and to continue developing the Sentinel System — a network of external data providers intended to enhance drug safety surveillance, among other efforts.

Because of the agency's huge workload, however, it has been difficult for the OND and OSE staff to meet their responsibilities in full, says the GAO report. An increase in staff is needed (perhaps double the staff for OSE by fiscal year 2011), says the GAO. In addition, the agency needs help fulfilling several committee vacancies to help in its decision-making.

www.gao.gov

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Behind the Headlines, Episode 18
Related Content

Young man having asthma attack or choking suffering from respiration problems | Image Credit: © Feodora - stock.adobe.com

UK Anaphylaxis Nasal Spray Approval Helps Reshape Emergency Allergy Treatment

Christopher Cole
July 18th 2025
Article

Newly approved needle-free adrenaline spray offers longer shelf life, better stability, and easier use, signaling a shift in emergency drug delivery design.


Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Patrick Lavery
May 30th 2025
Podcast

In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.


Kyiv, Ukraine - December 22, 2020: Backlit single shot image of GlaxoSmithKline logo on tv screen with a hand holding an Covid-19 vaccine concept | Image Credit: © Олександр Луценко - stock.adobe.com

FDA Approves Shingrix Prefilled Syringe to Simplify Vaccine Administration

Christopher Cole
July 17th 2025
Article


Site Logo

Transformations in Drug Development for Cell and Gene Therapies

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.


Site Logo

Innovations in Pregastric Absorption Drug Delivery & Orally Disintegrating Tablets

Catalent
July 16th 2025
Article

Site Logo

Rethinking Inhalation Drug Development

Experic
July 15th 2025
Article

What it takes to bring complex inhaled therapies to market—faster and smarter.

Related Content

Young man having asthma attack or choking suffering from respiration problems | Image Credit: © Feodora - stock.adobe.com

UK Anaphylaxis Nasal Spray Approval Helps Reshape Emergency Allergy Treatment

Christopher Cole
July 18th 2025
Article

Newly approved needle-free adrenaline spray offers longer shelf life, better stability, and easier use, signaling a shift in emergency drug delivery design.


Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Patrick Lavery
May 30th 2025
Podcast

In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.


Kyiv, Ukraine - December 22, 2020: Backlit single shot image of GlaxoSmithKline logo on tv screen with a hand holding an Covid-19 vaccine concept | Image Credit: © Олександр Луценко - stock.adobe.com

FDA Approves Shingrix Prefilled Syringe to Simplify Vaccine Administration

Christopher Cole
July 17th 2025
Article


Site Logo

Transformations in Drug Development for Cell and Gene Therapies

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.


Site Logo

Innovations in Pregastric Absorption Drug Delivery & Orally Disintegrating Tablets

Catalent
July 16th 2025
Article

Site Logo

Rethinking Inhalation Drug Development

Experic
July 15th 2025
Article

What it takes to bring complex inhaled therapies to market—faster and smarter.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.